Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

Size matters! Association between journal size and longitudinal variability of the Journal Impact Factor.

Koelblinger D, Zimmermann G, Weineck SB, Kiesslich T.

PLoS One. 2019 Nov 22;14(11):e0225360. doi: 10.1371/journal.pone.0225360. eCollection 2019.

2.

The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications.

Klieser E, Mayr C, Kiesslich T, Wissniowski T, Fazio PD, Neureiter D, Ocker M.

Int J Mol Sci. 2019 Oct 23;20(21). pii: E5266. doi: 10.3390/ijms20215266. Review.

3.

NRF2: The key to tumor- and patient-dependent chemosensitivity in biliary tract cancer?

Kiesslich T, Mayr C, Neureiter D.

EBioMedicine. 2019 Nov;49:9-10. doi: 10.1016/j.ebiom.2019.09.046. Epub 2019 Oct 21. No abstract available.

4.

Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.

Neureiter D, Stintzing S, Kiesslich T, Ocker M.

World J Gastroenterol. 2019 Jul 7;25(25):3136-3150. doi: 10.3748/wjg.v25.i25.3136. Review.

5.

Low VDAC1 Expression Is Associated with an Aggressive Phenotype and Reduced Overall Patient Survival in Cholangiocellular Carcinoma.

Feichtinger RG, Neureiter D, Kemmerling R, Mayr JA, Kiesslich T, Kofler B.

Cells. 2019 Jun 4;8(6). pii: E539. doi: 10.3390/cells8060539.

6.

Pancreatic cancer in young adults: changes, challenges, and solutions.

Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D.

Onco Targets Ther. 2019 May 6;12:3387-3400. doi: 10.2147/OTT.S176700. eCollection 2019. Review.

7.

HDAC inhibitors in liver cancer: which route to take?

Kiesslich T, Neureiter D.

Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):515-517. doi: 10.1080/17474124.2019.1605289. Epub 2019 Apr 17. No abstract available.

PMID:
30991854
8.

The Cancer Stem Cell Inhibitor Napabucasin (BBI608) Shows General Cytotoxicity in Biliary Tract Cancer Cells and Reduces Cancer Stem Cell Characteristics.

Beyreis M, Gaisberger M, Jakab M, Neureiter D, Helm K, Ritter M, Kiesslich T, Mayr C.

Cancers (Basel). 2019 Feb 26;11(3). pii: E276. doi: 10.3390/cancers11030276.

9.

Downregulation of SPARC Is Associated with Epithelial-Mesenchymal Transition and Low Differentiation State of Biliary Tract Cancer Cells.

Aghamaliyev U, Gaitantzi H, Thomas M, Simon-Keller K, Gaiser T, Marx A, Yagublu V, Araos J, Cai C, Valous NA, Halama N, Kiesslich T, Ebert M, Grützmann R, Rückert F, Breitkopf-Heinlein K.

Eur Surg Res. 2019;60(1-2):1-12. doi: 10.1159/000494734. Epub 2019 Jan 16.

PMID:
30650425
10.

Glycine Induces Migration of Microglial BV-2 Cells via SNAT-Mediated Cell Swelling.

Kittl M, Dobias H, Beyreis M, Kiesslich T, Mayr C, Gaisberger M, Ritter M, Kerschbaum HH, Jakab M.

Cell Physiol Biochem. 2018;50(4):1460-1473. doi: 10.1159/000494646. Epub 2018 Oct 25.

11.

Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.

Wanek J, Gaisberger M, Beyreis M, Mayr C, Helm K, Primavesi F, Jäger T, Di Fazio P, Jakab M, Wagner A, Neureiter D, Kiesslich T.

Int J Mol Sci. 2018 Oct 12;19(10). pii: E3128. doi: 10.3390/ijms19103128.

12.

Continuous, label-free, 96-well-based determination of cell migration using confluence measurement.

Mayr C, Beyreis M, Dobias H, Gaisberger M, Fuchs J, Pichler M, Ritter M, Jakab M, Helm K, Neureiter D, Kiesslich T.

Cell Adh Migr. 2019 Dec;13(1):76-82. doi: 10.1080/19336918.2018.1526612. Epub 2018 Oct 8.

13.

Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.

Primavesi F, Klieser E, Cardini B, Marsoner K, Fröschl U, Thalhammer S, Fischer I, Hauer A, Urbas R, Kiesslich T, Neureiter D, Zitt M, Klug R, Wundsam H, Sellner F, Karner J, Függer R, Cakar-Beck F, Kornprat P, Öfner D, Stättner S; ASSO pNEN Study Group.

Eur J Surg Oncol. 2019 Feb;45(2):198-206. doi: 10.1016/j.ejso.2018.08.016. Epub 2018 Sep 3.

PMID:
30262324
14.

HDAC-Linked "Proliferative" miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors.

Klieser E, Urbas R, Swierczynski S, Stättner S, Primavesi F, Jäger T, Mayr C, Kiesslich T, Fazio PD, Helm K, Neureiter D.

Int J Mol Sci. 2018 Sep 15;19(9). pii: E2781. doi: 10.3390/ijms19092781.

15.

The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.

Jäger T, Neureiter D, Fallaha M, Schredl P, Kiesslich T, Urbas R, Klieser E, Holzinger J, Sedlmayer F, Emmanuel K, Dinnewitzer A.

Strahlenther Onkol. 2018 Nov;194(11):991-1006. doi: 10.1007/s00066-018-1340-0. Epub 2018 Aug 1.

16.

Endoscopic submucosal dissection (ESD) for anal high-grade intraepithelial neoplasia: a case report.

Wagner A, Neureiter D, Holzinger J, Kiesslich T, Klieser E, Berr F.

Z Gastroenterol. 2018 May;56(5):495-498. doi: 10.1055/a-0578-9059. Epub 2018 May 7.

PMID:
29734448
17.

Miniaturization of the Clonogenic Assay Using Confluence Measurement.

Mayr C, Beyreis M, Dobias H, Gaisberger M, Pichler M, Ritter M, Jakab M, Neureiter D, Kiesslich T.

Int J Mol Sci. 2018 Mar 3;19(3). pii: E724. doi: 10.3390/ijms19030724.

18.

Thermographic real-time-monitoring of surgical radiofrequency and microwave ablation in a perfused porcine liver model.

Primavesi F, Swierczynski S, Klieser E, Kiesslich T, Jäger T, Urbas R, Hutter J, Neureiter D, Öfner D, Stättner S.

Oncol Lett. 2018 Mar;15(3):2913-2920. doi: 10.3892/ol.2017.7634. Epub 2017 Dec 18.

19.

Single-center implementation of endoscopic submucosal dissection (ESD) in the colorectum: Low recurrence rate after intention-to-treat ESD.

Wagner A, Neureiter D, Kiesslich T, Wolkersdörfer GW, Pleininger T, Mayr C, Dienhart C, Yahagi N, Oyama T, Berr F.

Dig Endosc. 2018 May;30(3):354-363. doi: 10.1111/den.12995. Epub 2018 Jan 3.

PMID:
29218732
20.

IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer.

Kessler SM, Lederer E, Laggai S, Golob-Schwarzl N, Hosseini K, Petzold J, Schweiger C, Reihs R, Keil M, Hoffmann J, Mayr C, Kiesslich T, Pichler M, Kim KS, Rhee H, Park YN, Lax S, Obrist P, Kiemer AK, Haybaeck J.

Oncotarget. 2017 Sep 21;8(52):89736-89745. doi: 10.18632/oncotarget.21116. eCollection 2017 Oct 27.

Supplemental Content

Loading ...
Support Center